GLP1R and obesity due to melanocortin 4 receptor deficiency: With previous success comes the hope that this approach will improve the landscape of chronic disease treatments, with one potential avenue being Glucagon-like peptide-1 (GLP-1) receptor agonists currently used to treat type 2 diabetes and obesity [162,163,164].